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A B S T R A C T   
The junctional adhesion molecule-A (JAM-A) is an adhesion molecule present in the surface of several cell types, 
such as endothelial cells and leukocytes as well as Dendritic Cells (DC). Given the potential relevance of JAM-A in 
diverse pathological conditions such as inflammatory diseases and cancer, we investigated the role of JAM-A in 
CD4+ T cell priming. We demonstrate that JAM-A is present in the immunological synapse formed between T 
cells and DC during priming. Furthermore, an antagonistic anti-JAM-A mAb could disrupt the interaction be-
tween CD4+ T cell and DC. Antagonism of JAM-A also attenuated T cell activation and proliferation with a 
decrease in T-bet expression and increased IL-6 and IL-17 secretion. These findings demonstrate a functional role 
for JAM-A in interactions between CD4+ T cells and DCs during T cell priming as a positive regulator of Th1 
differentiation.   
1. Introduction 
The junctional adhesion molecule-A (JAM-A/JAM-1/F11R) is a 
transmembrane glycoprotein expressed by platelets, epithelial cells, 
endothelial cells and leukocytes, such as dendritic cells (DC) [1–3]. The 
JAM-A extracellular region is composed of a membrane-distal V-type 
Ig-like domain (D1) and a membrane-proximal C2-type Ig domain (D2). 
JAM-A can undergo homophilic binding (JAM-A-JAM-A) under 
recruitment of D1 domains, or heterophilic binding through D2 domain 
interactions (JAM-A-LFA-1) or through interactions yet to be identified 
(JAM-A-CD9, αIIbβ3 or JAM-B) [4]. JAM-A plays a central role in 
leukocyte migration by modulating leukocyte-endothelial cell in-
teractions; however, JAM-A has not previously been implicated in in-
teractions between immune cells. 
During CD4+ T cell priming, DCs induce T cell activation, clonal 
expansion and differentiation into effector and memory cells. Several 
molecules present on the surface of T cells and DCs contribute to T cell 
activation. Among these are adhesion molecules, that not only ensure a 
strong cell-cell interaction, but can also trigger pathways that will 
dictate the fate of a naïve CD4+ T cell, such as the CD2-CD48 co-stim-
ulatory pathway [5] and TIGIT-CD155 [6], a co-inhibitory pathway. 
Given the potential of these pathways for therapeutic intervention in 
diverse pathological conditions, there is increasing interest in 
discovering molecules that would promote or disrupt CD4+ T cell-DC 
interaction. 
Considering that JAM-A is expressed by DCs and in view of its po-
tential relevance in several pathological conditions in which CD4+ T 
cells play dominant roles (e. g. autoimmune diseases and cancer) [4], we 
hypothesized that JAM-A may play a role in CD4+ T cell-DC interactions. 
We demonstrate that JAM-A is recruited into the immune synapse 
formed between CD4+ T cells and DC. We also demonstrate that JAM-A 
has a functional role in this interaction, as antagonism affected T cell 
activation, proliferation, differentiation and cytokine secretion. 
2. Materials and methods 
2.1. Mice 
Six to 12-week-old male and female C57BL/6 mice were purchased 
from Envigo (UK). OT-II transgenic mice containing T cells expressing T 
cell receptor (TCR) that recognizes the peptide 323–339 from chicken 
ovalbumin (OVA) bound to MHC-II molecule I-Ab [7] were bred 
in-house (Central Research Facilities, University of Glasgow). All ani-
mals were specific pathogen free and maintained in accordance with 
local and home office regulations. 
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2.2. DC-T cell co-culture and stimulation 
Bone marrow-derived DCs (BMDC) were prepared by culture in GM- 
CSF, as previously described [8]. On day 6, BMDCs were stimulated with 
LPS (100 ng/mL) for 24 h. Mature day 7-BMDCs were then pulsed with 
previously standardized optimal (1 μg/mL) (OVAhigh) or suboptimal 
(0.05 μg/mL) (OVAlow) concentrations of OVA peptide 323–339 (pOVA) 
(Sigma-Aldrich) and incubated with isolated CFSE-labelled CD4+ T cells 
from OT-II mice (1:10 DC:T cell ratio) under treatments with anti-JAM-A 
mAb or Rat IgG2bk isotype control (20 μg/mL). Cells were harvested 24, 
48 h or 72 h after the co-culture set-up for confocal microscopy (1 × 105 
DCs, 1 × 106 T cells), brightfield microscopy (4 × 103 DCs, 4 × 104 T 
cells) or flow cytometry (2 × 105 DCs, 2 × 106 T cells) analysis, 
respectively. Co-culture supernatants were used for detection of cyto-
kines by ELISA. 
2.3. Imaging 
For confocal images, DC-T cell co-cultures were fixed with 2% PFA 
for 20 min before being incubated with Fc block for 10 min and stained 
with fluorophore-conjugated antibodies anti-CD3-FITC (145–2C11), 
anti-CD11c-APC (N418), anti-MHC-II-eFluor 450 (HL3) and anti-JAM- 
A-PE (H202–106). Cells were added to an uncoated µ-slide I (Ibidi) to 
be analyzed with a ZEISS Cell Observer Spinning Disc Confocal Micro-
scope (Carl Zeiss) using a 63x objective lens. For widefield images, cells 
were cultured in a 384-well black tissue culture-treated plate with flat 
clear bottom (Corning) and treated with anti-JAM-A mAb BV11 (Merck) 
or its isotype control (BioLegend) (20 μg/mL). Cell clusters were visu-
alized using the brightfield of an EVOS FL Auto 2 microscope (Invi-
trogen). Acquisition of images was automated and tile scans from a 10x 
objective lens were merged using the microscope’s built-in software. All 
images were analyzed using Fiji open-source software [9]. Confocal 
images of individual BMDC-T cell clusters had their synapse area and the 
rest of the cell membrane determined using Fiji’s Polygon Selection tool. 
The fluorescence intensities of both areas were then measured, and the 
ratio was obtained by dividing the intensity from the synapse area by the 
rest of the cell membrane. Fiji’s Ellipse tool was used to detect the limits 
of all visible cell clusters. The area of the regions of interest were then 
measured and exported to a spreadsheet. In Microsoft Excel, a formula 
was used to automate the application of a threshold to exclude cell ag-
gregates smaller than 2000 μm2, the minimum area used to define a 
cluster [10]. Selections of cell aggregates smaller than 2000 μm2 were 
then excluded from sample images. 
2.4. Flow cytometry 
Single-cell suspensions were incubated with Fc Block for 10 min 
before adding fluorochrome-conjugated antibodies, as previously 
described [11]. Antibodies used (eBioscience, BD Biosciences or Bio-
Legend) were anti-CD4-eFluor 450 (RM4–5) or -FITC (GK1.5), 
anti-CD44-PE or -APC (IM7), anti-RORγt-APC (AFKJS-9), 
anti-T-bet-PE-Cy7 (4B10), anti-IFN-γ-PE (XMG1.2), anti-JAM-A-PE 
(H202–106) and CD45.1-eFluor 780 (A20). Prior to intracellular cyto-
kine staining, cells were stimulated with phorbol myristate acetate 
(PMA) (Sigma-Aldrich) (20 ng/mL) and ionomycin (Sigma-Aldrich) (1 
μg/mL) for 4 h in the presence of brefeldin A (BD Biosciences). For 
intracellular cytokine and transcription factor staining, a Cytofix/Cy-
toperm (BD Biosciences) and a FoxP3 (eBioscience) kit was used, 
respectively, according to the manufacturers’ instructions. Viability was 
assessed using a fixable cell viability dye (eBioscience) according to the 
manufacturer’s instructions. Cells were run on an LSR Fortessa (BD 
Biosciences) or LSR-II (BD Biosciences) and analyzed using FlowJo 
software (TreeStar). For generating tSNE plots, events were first 
downsized, and biological replicates were concatenated. 
2.5. ELISA 
Cytokine concentrations were measured from the co-culture super-
natants using ELISA MAX Standard Sets for Mouse IL-17 and IFN-γ 
(BioLegend) according to the manufacturer’s instructions. The absor-
bance was measured using a Sunrise Absorbance Reader (Tecan) at 450 
nm with subtraction of wavelengths from readings at 570 nm. 
2.6. Statistics 
Data is shown as mean ± SD. Specific tests and significance levels are 
indicated in the correspondent figure legends. Statistical analysis of 
results was performed using Prism version 6 (GraphPad Software, Inc, 
CA, USA). 
3. Results 
3.1. JAM-A is expressed by conventional DCs, but not naïve CD4+ T cells 
Prior to analyzing the effects of JAM-A blockade on the crosstalk 
between CD4+ T cells and DCs, we first examined the expression of JAM- 
A on the surface of these cell types from C57BL/6 J mice (identified as 
shown in Supplementary Fig. 1). Spleens and lymph nodes (LN) were 
digested in Collagenase D for a higher yield of adherent cells. LN resi-
dent JAM-A+ leukocytes (CD45+) were mostly composed of MHCII+, 
CD11c+ and CD11b+ cells, and only a small part of B220+ cells 
expressed JAM-A, suggesting that the JAM-A-expressing population is 
mainly formed by DCs and partly by B cells (Fig. 1A). In addition, NK 
(NK1.1+) and T cells (CD3+) did not appear to express relevant levels of 
JAM-A. When analyzing specific immune cell subsets, CD4+ T cells and 
plasmacytoid DCs (pDC) from both spleens and LNs expressed unde-
tectable to low levels of JAM-A (Fig. 1B). On the other hand, conven-
tional DCs (cDC) expressed JAM-A. Among these, LN cDC2 was the 
subset that expressed the highest levels, allowing the identification of a 
JAM-Ahigh population. LN resident cDC1 and cDC2 seemed to express 
higher levels than splenic cDC1 and cDC2, respectively. As cDCs express 
JAM-A, but not naïve CD4+ T cells, we analyzed the presence of a po-
tential ligand for JAM-A on the surface of CD4+ T cells. CD11a (LFA-1α) 
was highly expressed in naïve CD4+ T cells from LNs and spleens 
(Fig. 1C). 
3.2. JAM-A is present in the site of interaction during CD4+ T cell priming 
During T cell priming, both DCs and CD4+ T cells coordinate trans-
location of molecules that are relevant for the cells’ crosstalk to the 
immunological synapse (IS) [12]. To analyze if JAM-A is translocated to 
the IS during T cell priming, we first confirmed that JAM-A is also 
expressed on BMDCs (Fig. 2A). Surface expression of JAM-A by naïve 
(unstimulated) or activated (72h-antigen-stimulated) CD4+ T cells was 
also analyzed (Fig. 2B). Then, OT-II CD4+ T cells that were cultured with 
pOVA-pulsed-BMDCs for 24 h were analyzed with confocal microscopy 
for the expression of MHC-II, as a positive translocation control, CD11c, 
as a negative control, and JAM-A (Fig. 2C). The analysis of the MFI ratio 
between the inside and outside of the IS (IS/non-IS) (Fig. 2D) showed a 
higher concentration of MHC-II inside the IS in comparison with CD11c, 
but no difference between CD11c and JAM-A (Fig. 2E). Although JAM-A 
is not translocated to the IS, we show that this molecule is still present in 
the IS during T cell priming. 
3.3. JAM-A blockade during priming disrupts CD4+ T cell-DC cluster 
formation 
During T cell activation, DCs and T cells interact to form clusters, and 
interventions that affect cluster formation may reflect subsequent 
changes in T cell activation and function [13]. Given that JAM-A is a 
molecule that promotes cell-cell adhesion, we analyzed the capacity of 
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cells to form clusters during T cell priming under JAM-A blockade. As 
the literature describes similar in vitro effects in BMDCs under treatment 
with anti-JAM-A mAb BV11 and in JAM-A-deficient BMDCs (i.e. 
increased random motility) [2], we used this mAb antibody to block 
JAM-A intercellular ligation in T cell-DC cultures. OT-II CD4+ T cells 
were cultured with BMDCs pulsed with suboptimal or optimal concen-
trations of pOVA for 48 h under treatment with anti-JAM-A mAb or its 
isotype control and analyzed with widefield microscopy (Fig 3A). Under 
suboptimal conditions, groups treated with anti-JAM-A had lower 
numbers of clusters and total cluster area, but similar mean area of 
clusters in comparison with isotype-treated groups (Fig. 3B). Under 
optimal conditions, groups treated with anti-JAM-A had lower numbers 
of clusters but similar total cluster area, due to an increase in mean 
cluster size. The frequency distribution analysis showed that anti-JAM-A 
decreased the number of clusters smaller than 4000 μm2 (Fig. 3C). These 
data demonstrate that JAM-A plays a functional role in the interaction 
between CD4+ T cells and DC. 
3.4. JAM-A blockade during priming attenuates CD4+ T cell activation 
and proliferation 
To analyze if blockade of JAM-A pathways during T cell priming in 
vitro could promote changes in activation and proliferation of CD4+ T 
cells, BMDCs pulsed with optimal or suboptimal concentrations of pOVA 
were cultured with CFSE-labelled OT-II naïve CD4+ T cells for 72 h and 
analyzed by flow cytometry using CFSE dilution and CD44 expression as 
measures of cell proliferation and activation respectively. Treatment 
with anti-JAM-A mAb attenuated CD4+ T cell activation (Fig. 4A) and 
proliferation (Fig. 4B) under both concentrations of antigens in com-
parison with the isotype control groups, suggesting that JAM-A plays a 
role in T cell priming. 
3.5. JAM-A blockade during priming impacts CD4+ T cell differentiation 
and cytokine secretion 
T cell differentiation is key for successful T-cell responses, as 
different subsets secrete distinct cytokines that play specific roles during 
infection and in several pathological conditions. To analyze JAM-A 
blockade effects on CD4+ T cell differentiation in vitro, we used our T 
cell-DC in vitro assay to examine expression of key transcription factors 
regulating subset differentiation, T-bet (Th1) (Fig. 5A) and RORγt 
(Th17) (Fig. 5B). Anti-JAM-A mAb treatment decreased the proportion 
of CD4+ T-bet+ cells and the MFI of T-bet under both concentrations of 
antigen. A minor increase in the proportion of CD4+ RORγt+ cells was 
found under both activation conditions, while the suboptimal condition, 
but not optimal, also had an increase in RORγt MFI. To address the bias 
of decreased T cell activation/proliferation in the analysis of T cell dif-
ferentiation, we also analyzed the expression of T-bet in antigen- 
experienced T cells (Supplementary Fig. 2). The proportion of T-bet+
cells and T-bet MFI in CD44high cells were also significantly decreased, 
consistent with the data in Fig. 4. Cell supernatants were analyzed for 
the presence of key cytokines secreted by these specific T cell subsets, IL- 
Fig. 1. JAM-A is expressed by murine conventional DCs. Immune cells from C57BL/6 mice were analyzed by flow cytometry for the expression of JAM-A. (A) tSNE 
analysis of immune cells (CD45+) from LNs based on polychromatic flow cytometry data including JAM-A, CD11c, MHCII, CD11b, B220, NK1.1 and CD3 expression 
profiles, highlighting the population expressing the highest levels of JAM-A (solid black line) and the populations expressing respective lineage markers (dashed red 
line). (B) Representative histograms of JAM-A expression (solid line) or its isotype control (gray-shaded) on CD4+ T cells (B220− CD11c− CD3+ CD4+), pDCs (CD3−
NK1.1− CD11clow PDCA1+ B220+ CD11b− ), cDC1 (CD3− NK1.1− CD11chigh MHCII+ CD8+ CD11b− ) and cDC2 (CD3− CD11chigh MHCII+ CD8− CD11b+), from 
spleens and LNs. (C) Representative histograms of CD11a expression (solid line) or its isotype control (gray-shaded) on CD4+ T cells from spleens and LNs. Data are 
representative of an experiment performed in biological triplicates. 
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17 (Th17) and IFN-γ (Th1), as well as IL-6 (Fig. 6). No difference in IFN-γ 
secretion was found between groups that were stimulated under the 
same concentration of antigen. Although no difference in IL-17 con-
centration was found between groups under suboptimal activation 
conditions, anti-JAM-A treatment increased the secretion of IL-17 under 
optimal concentrations of antigen. In addition, anti-JAM-A treatment 
increased the concentration of IL-6 found in the supernatant of cells 
primed under optimal activation conditions. IL-6 plays an important role 
in T cell survival and is known to inhibit Th1 differentiation [14]. These 
results indicate that JAM-A positively regulates Th1 differentiation. 
Since anti-JAM-A treatment did not affect IFN-γ secretion but 
decreased T-bet expression, we analyzed if CD4+ T cells produce more 
IFN-γ when treated with anti-JAM-A during T cell priming. After being 
stimulated with antigen for 72 h, T cells were stimulated with PMA/ 
ionomycin and analyzed by flow cytometry for expression of intracel-
lular IFN-γ (Supplementary Fig. 3). Treatment with anti-JAM-A did not 
affect the proportion of CD4+ IFN-γ+ cells (Supplementary Fig. 3) nor 
the IFN-γ MFI in CD4+ cells or in populations of IFN-γ producers (not 
shown). 
4. Discussion 
We have shown that JAM-A is expressed by cDCs; in higher levels on 
LN cDC2, a subtype of DC that plays a dominant role in antigen pre-
sentation [15,16]. This higher expression of JAM-A on cDC2 populations 
in comparison with cDC1 also appears to happen in other lymphoid 
organs besides LNs and spleen, such as Peyer’s patches [17]. Similarly, 
BMDCs express high levels of JAM-A [2,3]. While both naïve and 
memory CD4+ T cells express undetectable to low levels of JAM-A, 
homophilic binding of JAM-A in the IS is therefore unlikely. This is 
supported by transcriptomics analysis that showed very low f11r 
expression in naïve and memory CD4+ T cells from the spleen of 
C57BL/6 mice (≤ 2 expression value normalized by DESeq2 from 
ImmGen Open Source Ultra-low-input RNA-seq data) [18]. On the other 
hand, CD4+ T cells express other potential ligands for JAM-A, such as 
LFA-1 [19]. We have demonstrated that JAM-A expressed by these cells 
is present in the IS during T cell priming. While translocation to the IS is 
well established for MHC-II/CD3 and has been observed in some T cell 
co-signaling molecules (i.e. LFA-1) [12], antigen-specific TCR-induced 
exclusion from the IS can occur with other molecules, such as CD43 [20, 
21]. Although JAM-A is not present in a higher proportion in the IS in 
comparison to the area outside the IS, our data demonstrates that DC 
Fig. 2. JAM-A is present in the site of interaction during CD4+ T cell priming. CD4+ T cells from OT-II mice were cultured with pOVA-pulsed BMDCs for 24 h and 
analyzed by confocal microscopy for the expression of CD11c, MHC-II and JAM-A. (A) Representative histograms of CD86 or JAM-A expression on immature (no LPS) 
or mature (LPS) BMDCs or in mature BMDCs stained with respective isotype controls. (B) Representative histograms of CD44 or JAM-A expression on unstimulated/ 
naïve (no OVA) or 72h-antigen-stimulated/activated (OVA) CD4+ T cells or in activated CD4+ T cells stained with respective isotype controls. (C) Representative 
confocal image stacks of CD4+ T cell recorded in the green channel (CD3) in contact with a BMDC identified by its expression of CD11c recorded in the red channel 
and MHC-II recorded in the blue channel and JAM-A recorded in the yellow channel. The scale bar represents 5 μm. (D) Representative confocal image stack with 
identification of the immunological synapse (IS) and the BMDC membrane outside the immunological synapse (non-IS). (E) Quantification of the ratio between the 
BMDC’s membrane MFI from the inside and the outside of the IS and comparison between JAM-A and MHC-II or CD11c. Results are expressed as mean ± SD of eight 
doublets with translocation of MHC-II to the IS. Statistical differences were determined using a one-way ANOVA. ns = non-significant, ****p ≤ 0.0001. 
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JAM-A is present in the IS and could be available for binding with po-
tential ligands from the T cell surface. 
Functional intracellular signaling cascades following JAM-A ligation 
are reported in non-immune cells [22], whereas the literature lacks 
studies on these effects in leukocytes [4]. On the other hand, JAM-A 
ligation to its potential ligands, such as LFA-1, might trigger, for 
instance, LFA-1-mediated signaling cascades [23]. Based on the evi-
dence of identifying JAM-A in the IS, and given that JAM-A is an 
adhesion molecule that provides firm attachment to cells during inter-
cellular interactions [1,24], we hypothesized that JAM-A intercellular 
binding could have a role in T cell/DC interactions. We therefore 
analyzed the capacity of T cells and DCs to form clusters under treatment 
with anti-JAM-A mAb. Under suboptimal activation conditions, the 
treatment decreased the number of clusters and total cluster area. Under 
optimal conditions, JAM-A blockade also decreased the number of 
clusters, but because the area of the clusters was in general larger, the 
total area occupied by them was unchanged in comparison with the 
isotype-treated group. It is unlikely that the blocking antibody affects DC 
development, as blockade was performed after differentiation and 
maturation of the BMDCs. In addition, JAM-A-deficient BMDCs were 
previously shown to express similar levels of maturation markers (CD80 
and CD86), surface molecules related to DC migration (CD11a, CD11b, 
CD11c, CD62L, JAM-B, and JAM-C) and antigen uptake capacity in 
comparison to WT BMDCs [2]. On the other hand, our data suggest that 
JAM-A blockade could be affecting DC adhesion. After priming T cells in 
vivo, DCs have to detach from T cells to present antigen to other cells or 
to play other immunomodulatory roles. Therefore, blockade of an 
adhesion molecule such as JAM-A could be modifying parameters as for 
Fig. 3. JAM-A blockade disrupts CD4+ T cell-DC cluster formation. CD4+ T cells from OT-II mice were cultured with BMDCs pulsed with suboptimal (OVAlow) or 
optimal (OVAhigh) concentrations of pOVA in the presence of anti-JAM-A mAb or its isotype control for 48 h and analyzed by widefield microscopy. (A) Repre-
sentative images of whole wells containing cell cultures, showing elliptical selections of cell clusters in white. Scale bar represents 500 μm. (B) Quantification of 
number, mean area and total area of clusters. (C) Frequency distribution of clusters’ area under optimal concentration of antigen and treated with anti-JAM-A mAb or 
its isotype control. Results are expressed as mean ± SD of replicate cultures. Statistical differences were determined using a two-way ANOVA or an unpaired Student’s 
t-test. *p ≤ 0.05, **** ≤ 0.0001. 
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example, intensity, area or duration of these intercellular interactions, 
consequently impairing this process and possibly delaying it. The anal-
ysis of clusters from 48h-co-cultures not only reflect cell interaction but 
also take into account T cell proliferation, as these are already dividing 
by this time point. To analyze if this physical disruption reflects changes 
in T cell outcomes, we cultured antigen-pulsed BMDCs with OT-II naïve 
CD4+ T cells for 72 h and examined their activation status and prolif-
eration. Treatment with anti-JAM-A mAb attenuated CD4+ T cell acti-
vation and proliferation both in suboptimal and in optimal 
concentrations of antigen. The impaired T cell proliferative response 
under JAM-A blockade might be a reflection of the diminished T cell 
activation status and seems to be reflected by the disruption in cluster 
formation. However, whereas the JAM-A ligand LFA-1 has been previ-
ously shown to be required for optimal T cell activation [25], we 
demonstrate that JAM-A only attenuates it, while it still provides sup-
port for T cell-DC interactions. 
To investigate if JAM-A plays a role on CD4+ T cell differentiation in 
vitro, we analyzed the expression of transcription factors that play a key 
role in this process, as well as cytokines commonly secreted by corre-
sponding subsets. JAM-A blockade promoted a minor increase in the 
expression of RORγt, as well as a small increase in the secretion of IL-17 
by CD4+ T cells stimulated under optimal activation conditions. 
Interestingly, previous literature describes a 4.5-fold increase on abso-
lute number of CD4+ IL-17+ T cells in the colonic lamina propria of JAM- 
A-deficient mice with C57BL/6 background in comparison with C57BL/ 
6 mice [26]. Induction of CD4+ T cell differentiation towards specific Th 
subsets is usually followed by inhibition of other subsets. T-bet, for 
example, is described to block transactivation RORC, responsible for 
encoding RORγt, and suppressing Th17 differentiation [27]. In addition, 
the genetic background of the JAM-A-deficient mice used in the previous 
study, as well as of the T cells used in our assays (C57BL/6), favors Th1 
development [28], which facilitates Th1 polarization studies [29]. We 
demonstrate that JAM-A blockade decreased T-bet expression by 
antigen-primed CD4+ T cells and increased IL-6 secretion in cultures 
from cells primed under optimal activation conditions. Although IL-6 
can be also produced by DCs, previous reports in the literature 
showed that BMDCs from JAM-A− /− mice did not alter their secretion of 
IL-10, IL-12p70, TNFα and IL-6 up to 24 h after LPS stimulation, 
compared with wild-type (WT) mice [30]. IL-6 plays an important role 
in CD4+ T cell differentiation, promoting IL-4-dependent Th2 polariza-
tion and inhibiting IL-4-independent Th1 differentiation [14]. Alto-
gether, these results suggest that DC JAM-A is required for optimal Th1 
differentiation. 
T-bet protein expression does not necessarily correlate with IFN-γ 
Fig. 4. JAM-A blockade attenuates CD4+ T cell activation and proliferation. CFSE-labelled CD4+ T cells from OT-II mice were cultured with BMDCs pulsed with 
suboptimal (OVAlow) or optimal (OVAhigh) concentrations of pOVA in the presence of anti-JAM-A mAb or its isotype control for 72 h and analyzed by flow cytometry 
for CD44 expression and CFSE fluorescence intensity. (A) Representative histograms of CD44 expression on CD4+ cells and quantification of the proportion of CD4+ T 
cells that are CD44high. (B) Representative histograms of CFSE fluorescence intensity on CD4+ cells and quantification of the proportion of CD4+ T cells that have 
divided based on the gating of CFSE fluorescence intensity. Results are expressed as mean ± SD of replicate cultures from three independent experiments. Statistical 
differences were determined using a two-way ANOVA. **p ≤ 0.01. 
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production [31], while it is required for this cytokine production [29], 
making it an early marker for Th1 cells. The role of IFN-γ as a positive 
regulator of T-bet expression, in addition to the capacity for T-bet to 
activate IFN-γ expression results in a hypothetical positive feedback loop 
during Th1 cell differentiation [32]. Anti-JAM-A mAb treatment did not 
affect the secretion of IFN-γ measured in the culture supernatant nor the 
production of IFN-γ measured intracellularly in cells from our cultures. 
This is supported by a study that showed no differences in IFN-γ con-
centrations from the supernatant of OVA-primed OT-II CD4+ T cells by 
BMDCs from JAM-A− /− mice in comparison with WT BMDCs [30]. T-bet 
is expressed in two consecutive waves: while its expression in the first 
48 h following CD4+ T cell primary activation requires IFN-γ signaling, 
later expression of T-bet is IFN-γ-independent [33]. Future investigation 
by possibly assessing T-bet expression in cells primed under blockade of 
Fig. 5. JAM-A blockade impairs T-bet expression by CD4+ T cells. 
CD4+ T cells from OT-II mice were cultured with BMDCs pulsed 
with suboptimal (OVAlow) or optimal (OVAhigh) concentrations of 
pOVA in the presence of anti-JAM-A mAb or its isotype control for 
72 h and analyzed by flow cytometry for the expression of different 
transcription factors. (A) Representative dot plots of T-bet or (B) 
RORγt intracellular expression in CD4+ T cells, quantification of the 
proportion of cells expressing the transcription factors based on the 
fluorescence emitted by its matched isotype controls and quantifi-
cation of their MFI. Results are expressed as mean ± SD of replicate 
cultures. Statistical differences were determined using a two-way 
ANOVA. *p ≤ 0.05, **p ≤ 0.01, *** ≤ 0.001, **** ≤ 0.0001.   
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JAM-A pathways at earlier time points will determine the effects of 
JAM-A blockade in the distinct waves of T-bet expression and further 
our understanding of JAM-A role in Th1 differentiation and function. 
Our data demonstrate that JAM-A expressed by DCs regulates CD4+
T cell-DC interactions during T cell priming. JAM-A is present in the IS 
formed between T cells and DC during T cell priming. Blockade of JAM- 
A in vitro disrupted CD4+ T cell-DC cell cluster formation in cells 
cultured for 48 h and attenuated T cell activation and proliferation in 
cells analyzed 72 h after priming. In addition, JAM-A blockade in vitro 
decreased the expression of T-bet, supporting a role for JAM-A as a 
regulator of Th1 differentiation. These findings highlight the relevance 
of JAM-A in regulating immune responses in the context of 
inflammation. 
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